Cardiovascular
Novo Nordiskās Wegovy boosts heart health, J.P. Morgan predicts $71B GLP-1 market by 2032
Anika Sharma
The demand for Novo Nordisk’s obesity medications is surging, with production capacity being the primary limiting factor in the short ...
Amgen’s Groundbreaking Discovery: Unleashing the Potential of Olpasiran Beyond Expectations
Anika Sharma
In a revelation that promises to reshape the landscape of cardiovascular health, biotechnology giant Amgen has unveiled extraordinary findings from ...
Merck’s Bold Bet: 6-Year Study on Oral PCSK9 Inhibitor Dominates Phase 3 Program
Anika Sharma
In the ever-evolving landscape of pharmaceutical breakthroughs, Merck & Co. has set its sights on a pioneering endeavor that could ...
leading obesity medication Wegovy’s ‘best-case scenario’ Novo Nordisk published cardiac results statistics
SG Tylor
Source – Novo Nordisk Novo Nordisk has been capitalizing on the momentum generated by its weight loss drug, Wegovy, which ...
Astellas and Eko Partner for Heart Failure Digital Therapeutics with Eko CORE 500ā¢ Stethoscope
SG Tylor
Source – Astellas Pharma Astellas has obtained the licensing rights to a smart stethoscope device developed by Eko Health, with ...
